Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period June 3, 2022 through June 3, 2024 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the activity, totaling 2.0 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
2.0 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
In this web-based program, physicians will learn how recent developments in sensor-based continuous glucose monitoring have advanced the management of Type 2 and Type 1 diabetes.
June 3, 2022
June 3, 2024
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with type 2 or type 1 diabetes, including endocrinologists, diabetes specialists, primary care physicians, and related clinicians.
Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
This activity is supported by an independent medical education grant from Abbott Diabetes Care.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Vivian Fonseca, MD – Program Chair
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
Consulting: Takeda, Novo Nordisk, Sanofi – Aventis, Eli, Abbott, AstraZeneca, Intarcia, Asahi
Research Support (To Tulane): Grants from Bayer and Boehringer Ingelheim
Stock Options: Microbiome Technologies, Insulin Algorithms, BRAVO4Health.
Richard Bergenstal, MD
International Diabetes Center- Park Nicollet
Clinical Research, Scientific Advisory Board, and/or Consultant: Abbott Diabetes Care, Ascenia, CeQur, Dexcom, Eli Lilly, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi, Senseonics and United Healthcare
Eugene Wright, MD
Consulting Associate, Departments of Medicine
Duke University Medical Center Durham, NC
Inaugural Chair, ADA Primary Care Interest Group
Medical Director for Performance Improvement Charlotte Area Health Education Center
Speakers’ Bureau: Abbott Diabetes, Bayer, BI, Eli Lilly, and Sanofi
Advisory boards: Abbott Diabetes, Bayer, BI, Eli Lilly, Medtronic, and Sanofi
Consultant: Abbott Diabetes, Bayer, BI, and Eli Lilly
Eden Miller, DO
Diabetes and Obesity Care LLC
St. Charles Hospital
Advisor or consultant: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi Aventis
Speaker or Speakers Bureau: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk
Program Managers and Web Editor Disclosure
Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.
Upon completion of this activity, participants will be able to:
- Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for patients with T1D and T2D.
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate patients with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in patients with T1D and T2D.
- Identify which patients with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
- Interpret and apply data and results from clinical trials and experts with experience in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T1D and T2D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
- Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care setting; and understand the translational implications of deploying sensor-based, CGM-based technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
- Educate other clinical providers on the diabetes care team about the rationale, role, evidence, and outcome-enhancing results that are derived from employing technology-based CGM strategies—both patient- and physician-directed—across the broad spectrum of patients with diabetes
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
· We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
· For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
· We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
· If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Copyright © 2022 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations